On July 14, 2017, Huada Gene was officially listed on the GEM of the Shenzhen Stock Exchange. It also became the first non-backdoor A-share company in the domestic genetic industry. Since then, the stock price of Huada has been rising all the time, and its market value has exceeded 100 billion.
However, a recent report titled "Hua Da Gene IPO Data Lies, Project Has Been Reported by 3,000 Joint Reports" has pushed Huada Gene to the forefront, saying that the financial data of the report of the Huada Gene IPO has a significant The difference, but there is no explanation and explanation. At the same time, the article also stated that the Huada Gene Project was stationed in the Dameisha District of Shenzhen and was reported by more than 3,000 people. The relevant lawsuits were not disclosed in the declaration. Affected by the incident, the stock price of Huada Gene once fell to a limit. As of November 28, the company's market value has shrunk to 80 billion.
Just yesterday (November 27), the Shenzhen Stock Exchange Huada Gene issued an inquiry letter. On the same evening, Huada Gene released an announcement, and responded to the Shenzhen Stock Exchange’s inquiry letter and the contents of the media report. Reply.
Question 1: In the two versions of the IPO declaration submitted by the company on December 11, 2015 and March 14, 2017, the reason for the inconsistent production and sales of reproductive health services in 2014.
Reply:
1. The data difference between the two pre-disclosure drafts of the prospectus is caused by different statistical calibers.
After verification, the reason for the difference in data disclosed twice was caused by different statistical calibers. The company submitted the prospectus (pre-disclosure draft) on December 11, 2015 and March 14, 2017 respectively. The statistical caliber of the 2015 prospectus is the number of samples actually detected during the company's production process. The internal caliber), that is, the “number of machinesâ€; the statistical caliber of the 2017 prospectus is the number of samples (outside caliber) of the actual delivery customer's test report, that is, the “report numberâ€.
In order to objectively reflect the company's production capacity and capacity utilization rate, the company's prospectus (declaration draft) in 2015, taking into account the characteristics of the emerging industry of genetic testing, is significantly different from the traditional physical form of production and processing enterprises, choose to use The number of actual test samples produced by the production delivery center (“number of machines on the machineâ€) is used as the statistical measure of the current year's output, and the sales volume of the year is launched according to the characteristics of “sales by sales†in the industry.
In the part of product and sales information disclosure, the number of samples of internal R&D and quality control is excluded, and the production and sales samples of the company during the reporting period are re-disclosed according to the actual number of inspection reports delivered by the examinee, which can better meet the income of the financial section of the prospectus. Matching the unit price information, more in line with the concept of actual external production and sales, easy for investors to understand, and reducing the sample size is a more robust treatment, so the disclosure of the 2017 prospectus is adjusted to the external sample size. The number of samples that will ultimately be delivered to the test report.
2. The adjustment of production and sales of reproductive health products has no effect on the disclosure of relevant financial information in the prospectus.
The prospectus disclosed in 2017 decreased by approximately 90,400 compared with the 2014 production and sales data in the 2015 disclosure prospectus. The change in data statistics does not affect the actual delivery report quantity and sales amount of the company's testing service. It will have an impact on the company's balance sheet and income statement and cash flow statement during the reporting period, and will not affect investors' judgment on the company's profitability and future development trend.
In summary, the relevant financial data of the company were audited by Ernst & Young Hua Ming Certified Public Accountants (special general partnership). The financial information of the company was true and accurate, which was in line with the actual operation of the company; the sponsor institution CITIC Securities Co., Ltd. also carried out corresponding verification. The adjustment of the statistics of the above-mentioned production and sales data does not have a retrospective adjustment of the company's disclosed financial information.
Question 2: The controlling shareholder of the company is involved in litigation cases related to the construction of the Huada Gene Center and the Shenzhen Construction Land Planning Permit of BH-2011-0032. Please inform the company whether the current progress of the above-mentioned cases and the impact on the company are undisclosed.
Reply:
The media reported that the report of the Huada Gene Prospectus did not disclose the case concerning the opposition of its controlling shareholder Shenzhen Huada Gene Technology Co., Ltd. due to the project construction project in Dameisha, Shenzhen, and the three administrative cases. No. 1962, (2014) Yuexing Shen 1522, (2016) Yuexing Shen 1523, respectively.
The three administrative litigation cases were caused by a series of administrative litigations initiated by some residents in the vicinity of Huada Holdings’ investment in the construction of a bio-industry development base project in Dameisha, Yantian District, including “Zeng Wenying and other five former people who told Shenzhen’s living environment. Committee Cases, “Zheng Qiang v. Shenzhen Planning and Land Resources Committee Caseâ€, “Chen Yizhong v. Shenzhen Planning and Land Resources Committee Caseâ€.
As of the time when Huada Gene was first declared, the above cases were all terminated at the first instance. The first-instance judgments all ruled that the plaintiff lost the case. The results of these judgments are beneficial to Huada Holdings. After the initial application to the date of this announcement, “Zheng Qiang v. Shenzhen City Planning Both the case of the Land and Resources Committee and the case of Chen Yizhong v. Shenzhen Planning and Land Resources Committee ended the final trial, and all the plaintiffs were defeated; "Zeng Wenying and other five former cases told the Shenzhen Habitat Environment Committee" are still at The trial stage of the second instance is still pending final judgment. The follow-up progress of the above cases did not adversely affect Huada Holdings. During the lawsuit, there were no obstacles such as suspension of construction and suspension of construction projects.
After verification, Huada Holdings legally obtained the land use right and fulfilled the relevant procedures for project construction according to law. The project does not involve animal living experiments, does not involve genetic modification experiments, the environmental protection perspective is feasible, and the plaintiffs have misunderstandings on the environmental impact. At present, the construction project of Huada Holdings is still in the process of construction, and Huada Gene has not used the construction project land.
The company or Huada Holdings is a plaintiff or defendant in a non-litigation case. Huada Holdings only participates in the lawsuit as a third party in the case. The above three administrative lawsuits involving Huada Holdings as a third party are not yet settled by Huada Holdings. Foreseeable major lawsuits, arbitrations and administrative penalties. According to the Securities Law, the Measures for the Administration of Initial Public Offerings and Listing on the Growth Enterprise Market, the above three administrative lawsuits involving Huada Holdings as a third party are not legal disclosures, and the company's prospectus need not be disclosed. .
Disposable Use Puncture Guider
Disposable Use Puncture Guider,All Laparoscopic Instruments,Keyhole Surgery Instruments,Surgical Laparoscopic Machine
Changzhou Weipu Medical Devices Co., Ltd. , https://www.cnweipumedical.com